Reversed phase gives the most information per run, but cannot see aggregates, size-exclusion sees aggregates, but not sequence variants, and mass spectrometry confirms identity but depends on a clean upstream separation
Preclinical evidence supports the role of GLP-1RAs in alleviating neuropathic pain through the modulation of microglial activity, inflammatory cytokine production and -endorphin release [63, 65, 68, 70,71,72,73,74]
In vitro DDI studies detailed in clinical pharmacology and biopharmaceutics reviews were not included for exenatide and dulaglutide, but were included for liraglutide, semaglutide, and tirzepatide (Table 3)
According to a 2024 review, There were no serious adverse events attributed directly to [urolithin A] reported in any of the studies
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG